Table 1.
Clinical trials evaluating CAR-T cell therapy in gliomas.
| NCT Number | Other IDs | Cancer Type | Study Results | CAR-T | Phases | Study Status | Treatment |
|---|---|---|---|---|---|---|---|
| NCT02664363 | Pro00069444 | Newly Diagnosed GBM During Lymphopenia | Y | EGFRvIII CAR-T cells | PHASE 1 | T | EGFRvIII CAR-T cells |
| NCT01454596 | 110266|11-C-0266 | Malignant Gliomas Expressing EGFRvIII | Y | EGFRvIII CAR-T cells | PHASE 1|PHASE 2 | C | 1/Phase I Arm: Escalating doses of EGFRvIII CAR-T cells transduced peripheral blood lymphocytes (PBL) 2/Phase II Arm: Maximum tolerated dose of anti-EGFRvIII CAR-T transduced PBL established in Phase 1 |
| NCT06482905 | TX103T-RG008 | Recurrent or Progressive Grade 4 Glioma | N | B7-H3 CAR-T (TX103) | PHASE 1 | NR | Cohort A: Single delivery routes: Anti-B7-H3/TX103 CAR-T cells Cohort B: Dual delivery route: Anti-B7-H3/TX103 CAR-T cells |
| NCT06186401 | 23704|5U19CA264338-03 | Newly diagnosed EGFRvIII+ Glioblastoma | N | EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells | PHASE 1 | R | Cohort 1 Starting Dose: E-SYNC CAR-T cells Cohort 1 Dose-escalation: E-SYNC CAR-T cells Cohort 2 Tissue analysis cohort: EGFRvIII H-score of >=250: Maximum tolerated E-SYNC CAR-T cells dose EGFRvIII H-score of <250: Recommended E-SYNC CAR-T cells dose based on results from cohort 1 |
| NCT05868083 | SNC-109-101 | Recurrent Glioblastoma | N | SNC-109 CAR-T cells | PHASE 1 | R | SNC-109 CAR-T cell therapy |
| NCT05802693 | A03728 | Recurrent Glioblastoma | N | EGFRvIII CAR-T cells |
EARLY PHASE 1 | NR | EGFRvIII CAR-T cell therapy |
| NCT05660369 | 22-175 | Glioblastoma | N | CARv3-TEAM-E T Cells | PHASE 1 | R | Safety Run-In Phase: 1 infusion of CARv3-TEAM-E Arm 1 Recurrent GBM, EGFRvIII Positive: CARv3-TEAM-E Arm 2 Newly Diagnosed GBM, EGFRvIII Positive: CARv3-TEAM-E Arm 2 Newly Diagnosed GBM, EGFRvIII Negative: CARv3-TEAM-E |
| NCT05627323 | CHM-1101-001 | MMP2+ Recurrent or Progressive Glioblastoma | N | CHM-1101 CAR-T cells | PHASE 1 | NR | Arm 1: Dose level 1 CHM-1101 CAR-T cells Arm 2: Dose level 2 CHM-1101 CAR-T cells |
| NCT05577091 | TTSW2021-01 | Recurrent Glioblastoma | N | Autologous Tris-CAR-T cells | PHASE 1 | R | Autologous Tris-CAR-T cells |
| NCT05474378 | IRB-65002|NCI-2022-06043 | Recurrent Glioblastoma | N | B7-H3 CAR-T cells | PHASE 1 | R | Arm 1 Dose escalation: B7-H3CAR-T Arm 2 Dose Expansion: B7-H3CAR-T |
| NCT05366179 | LCCC2059-ATL | Recurrent or Refractory Glioblastoma | N | B7-H3 CAR-T cells | PHASE 1 | R | CAR.B7-H3T cells therapy |
| NCT05353530 | IRB202200057 | CD70+ Adult GBM | N | 8R-70CAR-T cells | PHASE 1 | R | Single dose of 8R-70CAR-T cell therapy |
| NCT05241392 | TX103T-IG005 | Recurrent Glioblastomas | N | B7-H3-targeting CAR-T cells | PHASE 1 | R | B7-H3-targeting CAR-T cell therapy |
| NCT05131763 | Fudan-Changchun | Relapsed/Refractory NKG2DL+ Solid Tumors | N | NKG2D-based CAR-T cells | PHASE 1 | U | NKG2D-based CAR-T cell therapy |
| NCT05063682 | 6678EGFRvIII | Leptomeningeal Glioblastoma | N | EGFRvIII-CAR-T cells | PHASE 1 | U | EGFRvIII-CAR-T cell therapy |
| NCT04661384 | 19497|NCI-2020-06010|19497|P30CA033572 | Adult with Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma | N | IL13Ralpha2-CAR-T cells | PHASE 1 | R | IL13Ralpha2-CAR-T cells therapy |
| NCT04385173 | SAHZJU-BP102 | Recurrent and Refractory Glioblastoma | N | B7-H3 CAR-T | PHASE 1 | R | B7-H3 CAR-T between cycles of Temozolomide treatment |
| NCT04270461 | JiujiangUH | Relapsed/Refractory NKG2DL+ Solid Tumors | N | NKG2D-based CAR-T cells | PHASE 1 | W | NKG2D-based CAR-T cells therapy |
| NCT04214392 | 19309|NCI-2019-08393|19309 | MMP2+ Recurrent or Progressive Glioblastoma | N | Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR-T-lymphocytes | PHASE 1 | R | Arm 1: Chlorotoxin-CD28-CD3z-CD19t-expressing CAR-T cells, ICT delivery Arm 2: Chlorotoxin-CD28-CD3z-CD19t-expressing CAR-T cells, ICT/ICV dual delivery |
| NCT04077866 | SAHZJU-RCT-BP102 | Recurrent or Refractory Glioblastoma | N | B7-H3 CAR-T | PHASE 1|PHASE 2 | R | Arm 1: Temozolomide alone Arm 2: Temozolomide + B7-H3 CAR-T therapy |
| NCT04045847 | Chen Zhinan-2 | Recurrent Glioblastoma | N | CD147-CART | EARLY PHASE 1 | U | CD147-CAR-T therapy |
| NCT04003649 | 18251|NCI-2018-02764|18251|R01CA236500 | Resectable Recurrent Glioblastoma | N | IL13Ralpha2 CAR-T cells | PHASE 1 | R | Arm I: Nivolumab + Ipilimumab + IL13Ralpha2 CAR-T cells Arm II: Nivolumab + IL13Ra2 CAR-T cells Arm III: IL13Ra2 CAR-T cells |
| NCT03726515 | 831706, UPCC 13318 | Newly Diagnosed, MGMT-Unmethylated Glioblastoma | N | CART-EGFRvIII T cells | PHASE 1 | C | CART-EGFRvIII + Pembrolizumab |
| NCT03283631 | Pro00083828|5P50CA190991-03 | Recurrent Glioblastoma | N | EGFRvIII-CARs | PHASE 1 | T | EGFRvIII-CARs therapy |
| NCT03170141 | GIMI-IRB-17003 | Glioblastoma | N | Antigen-specific IgT cells | PHASE 1 | R | Antigen-specific IgT cells therapy |
| NCT02937844 | SBNK-2016-016-01 | Recurrent Glioblastoma | N | Anti-PD-L1 CSR T cells | PHASE 1 | U | Anti-PD-L1 CAR-T cells therapy |
| NCT02844062 | SBNK-2016-015-01 | Recurrent Glioblastoma | N | anti-EGFRvIII CAR-T cells | PHASE 1 | U | Anti-EGFRvIII CAR-T cells therapy |
| NCT02209376 | UPCC 35313, 820381 | EGFRVIII+ Glioblastoma | N | CART-EGFRvIII T cells | PHASE 1 | T | CART-EGFRvIII T cells therapy |
T = terminated; C = completed; NR = not recruiting; R = recruiting; W = withdrawn; U = unknown; Y = yes; N = no.